Industries > Pharma > Hereditary Angioedema Treatment Market Report 2021-2031
Hereditary Angioedema Treatment Market Report 2021-2031
By Drug Class (C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), By Treatment (Prophylaxis, and On-demand), By Route of Administration (Intravenous, Subcutaneous and Oral), By Type (Type I HAE, Type II HAE, Type III HAE), By Drug Type (Generic Drugs, and Branded Drugs), By Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Leading Regional/ Country market analysis
Hereditary Angioedema Treatment Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Hereditary Angioedema Treatment is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 290+ page report provides 490+ tables and 470+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Hereditary Angioedema Treatment Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Hereditary Angioedema Treatment Market By Drug Class
• C1-esterase inhibitor
o Plasma
o Berinert, Cinryze, and Haegarda
o Recombinant
• Bradykinin B2 receptor antagonist
• Kallikrein inhibitor
o Kalbitor
o Takhzyro
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Hereditary Angioedema Treatment Market By Treatment
• Prophylaxis
• On-demand
• Revenue and growth forecasts from 2021 to 2031 for the Global Hereditary Angioedema Treatment Market By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Revenue and growth forecasts from 2021 to 2031 for the Global Hereditary Angioedema Treatment Market By Type
• Type I HAE
• Type II HAE
• Type III HAE
• Revenue and growth forecasts from 2021 to 2031 for the Global Hereditary Angioedema Treatment Market By Patient Demographics
• Geriatric Patient
• Adult Patient
• Pediatric
• Revenue and growth forecasts from 2021 to 2031 for the Global Hereditary Angioedema Treatment Market By End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Hereditary Angioedema Treatment Market By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Hereditary Angioedema Treatment Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Hereditary Angioedema Treatment Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Hereditary Angioedema Treatment Market report helps you
In summary, our 290+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Hereditary Angioedema Treatment Market, with forecasts for Get our report today Hereditary Angioedema Treatment Market Forecast 2021-2031: By Drug Class, Treatment, Route of Administration, By Type Drug Type, Patient Demographics, End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Hereditary Angioedema Treatment market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Hereditary Angioedema Treatment Market. Some of the company’s profiled in this report include
• Shire Plc
• BioCryst Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Pharming Group N.V.
• CSL Limited
• Attune Pharmaceuticals, Inc.
• Adverum Biotechnologies, Inc.
• KalVista Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Pharming Healthcare, Inc.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Hereditary Angioedema Treatment Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Hereditary Angioedema Treatment Market Report 2021-2031: By Drug Class (C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), By Treatment (Prophylaxis, and On-demand), By Route of Administration (Intravenous, Subcutaneous and Oral), By Type (Type I HAE, Type II HAE, Type III HAE), By Drug Type (Generic Drugs, and Branded Drugs), By Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Hereditary Angioedema Treatment Market
2.1. Hereditary Angioedema Treatment Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Hereditary Angioedema Treatment Market Overview
3.1. Global Hereditary Angioedema Treatment Market Size and Forecast By Region
3.2. Global Hereditary Angioedema Treatment Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Prevalence of hereditary angioedema disorders
3.3.1.2. Increasing geriatric population around the World
3.3.1.3. Increasing therapeutic advancement in hereditary angioedema treatment
3.3.1.4. Increasing strategic initiatives in hereditary angioedema treatment market
3.3.1.5. Surging investment in hereditary angioedema treatment
3.3.2. Market Restraints
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High Cost of development
3.3.2.3. Product Recall
3.3.3. Opportunities
3.3.3.1. Increasing focus on advance therapeutics
3.3.3.2. Increasing focus on healthcare infrastructure
3.3.4. Challenges
3.3.4.1. Safety consideration in storage & transportation
3.3.4.2. Increasing competition in the market
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Hereditary Angioedema Treatment Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. C1-esterase Inhibitor
4.1.1.1. C1-esterase Inhibitor Market size and forecast, 2021-2031 (USD Million)
4.1.2. Bradykinin B2 Receptor Antagonist
4.1.2.1. Bradykinin B2 Receptor Antagonist Market size and forecast, 2021-2031 (USD Million)
4.1.3. Kallikrein Inhibitor
4.1.3.1. Kallikrein Inhibitor Market size and forecast, 2021-2031 (USD Million)
4.1.4. Others
4.1.4.1. Others Market size and forecast, 2021-2031 (USD Million)
5. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Treatment (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Prophylaxis
5.1.1.1. Prophylaxis Market size and forecast, 2021-2031 (USD Million)
5.1.2. On-demand
5.1.2.1. On-demand Market size and forecast, 2021-2031 (USD Million)
6. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Type I HAE
6.1.1.1. Type I HAE Market size and forecast, 2021-2031 (USD Million)
6.1.2. Type II HAE
6.1.2.1. Type II HAE Market size and forecast, 2021-2031 (USD Million)
6.1.3. Type III HAE
6.1.3.1. Type III HAE Market size and forecast, 2021-2031 (USD Million)
7. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Geriatric Patient
7.1.1.1. Geriatric Patient Market size and forecast, 2021-2031 (USD Million)
7.1.2. Adult Patient
7.1.2.1. Adult Patient Market size and forecast, 2021-2031 (USD Million)
7.1.3. Pediatric
7.1.3.1. Pediatric Market size and forecast, 2021-2031 (USD Million)
8. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Generic Drugs
8.1.1.1. Generic Drugs Market size and forecast, 2021-2031 (USD Million)
8.1.2. Branded Drugs
8.1.2.1. Branded Drugs Market size and forecast, 2021-2031 (USD Million)
9. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Oral
9.1.1.1. Oral Market size and forecast, 2021-2031 (USD Million)
9.1.2. Subcutaneous
9.1.2.1. Subcutaneous Market size and forecast, 2021-2031 (USD Million)
9.1.3. Intravenous
9.1.3.1. Intravenous Market size and forecast, 2021-2031 (USD Million)
10. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals
10.1.1.1. Hospitals Market size and forecast, 2021-2031 (USD Million)
10.1.2. Homecare
10.1.2.1. Homecare Market size and forecast, 2021-2031 (USD Million)
10.1.3. Specialty Clinics
10.1.3.1. Specialty Clinics Market size and forecast, 2021-2031 (USD Million)
10.1.4. Others
10.1.4.1. Others Market size and forecast, 2021-2031 (USD Million)
11. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.1.1. Hospitals Pharmacy
11.1.1.1. Hospitals Pharmacy Market size and forecast, 2021-2031 (USD Million)
11.1.2. Retail Pharmacy
11.1.2.1. Retail Pharmacy Market size and forecast, 2021-2031 (USD Million)
11.1.3. Online Pharmacies
11.1.3.1. Online Pharmacies Market size and forecast, 2021-2031 (USD Million)
12. North America Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. North America Hereditary Angioedema Treatment Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. North America Hereditary Angioedema Treatment Market Size and Forecast By Treatment
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. North America Hereditary Angioedema Treatment Market Size and Forecast By Drug Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. North America Hereditary Angioedema Treatment Market Size and Forecast By Patient Demographics
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. North America Hereditary Angioedema Treatment Market Size and Forecast By Type
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. North America Hereditary Angioedema Treatment Market Size and Forecast By Route of Administration
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. North America Hereditary Angioedema Treatment Market Size and Forecast By End-User
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. North America Hereditary Angioedema Treatment Market Size and Forecast By Distribution Channel
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. U.S. Hereditary Angioedema Treatment Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Canada Hereditary Angioedema Treatment Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Europe Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Europe Hereditary Angioedema Treatment Market Size and Forecast By Drug Class
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Europe Hereditary Angioedema Treatment Market Size and Forecast By Treatment
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Europe Hereditary Angioedema Treatment Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Europe Hereditary Angioedema Treatment Market Size and Forecast By Type
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Europe Hereditary Angioedema Treatment Market Size and Forecast By Drug Type
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Europe Hereditary Angioedema Treatment Market Size and Forecast By Route of Administration
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Europe Hereditary Angioedema Treatment Market Size and Forecast By End-User
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Europe Hereditary Angioedema Treatment Market Size and Forecast By Distribution Channel
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. UK Hereditary Angioedema Treatment Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Germany Hereditary Angioedema Treatment Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. France Hereditary Angioedema Treatment Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
13.13. Rest of Europe Hereditary Angioedema Treatment Market
13.13.1.1. XX Driving/Opportunity Factor
13.13.1.2. XX Driving/Opportunity Factor
14. Asia Pacific Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Drug Class
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Treatment
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Type
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Drug Type
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Route of Administration
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By End-User
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Distribution Channel
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. China Hereditary Angioedema Treatment Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. India Hereditary Angioedema Treatment Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
14.12. Japan Hereditary Angioedema Treatment Market
14.12.1.1. XX Driving/Opportunity Factor
14.12.1.2. XX Driving/Opportunity Factor
14.13. Rest of Asia Pacific Hereditary Angioedema Treatment Market
14.13.1.1. XX Driving/Opportunity Factor
14.13.1.2. XX Driving/Opportunity Factor
15. Latin America Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Drug Class
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Treatment
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Patient Demographics
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Drug Type
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Type
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Route of Administration
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. Latin America Hereditary Angioedema Treatment Market Size and Forecast By End-User
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Distribution Channel
15.10. Brazil Hereditary Angioedema Treatment Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Mexico Hereditary Angioedema Treatment Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
15.12. Rest of Latin America Hereditary Angioedema Treatment Market
15.12.1.1. XX Driving/Opportunity Factor
15.12.1.2. XX Driving/Opportunity Factor
16. MEA Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
16.1. Market Overview
16.2. MEA Hereditary Angioedema Treatment Market Size and Forecast By Drug Class
16.2.1.1. XX Driving/Opportunity Factor
16.2.1.2. XX Driving/Opportunity Factor
16.3. MEA Hereditary Angioedema Treatment Market Size and Forecast By Treatment
16.3.1.1. XX Driving/Opportunity Factor
16.3.1.2. XX Driving/Opportunity Factor
16.4. MEA Hereditary Angioedema Treatment Market Size and Forecast By Patient Demographics
16.4.1.1. XX Driving/Opportunity Factor
16.4.1.2. XX Driving/Opportunity Factor
16.5. MEA Hereditary Angioedema Treatment Market Size and Forecast By Drug Type
16.5.1.1. XX Driving/Opportunity Factor
16.5.1.2. XX Driving/Opportunity Factor
16.6. MEA Hereditary Angioedema Treatment Market Size and Forecast By Type
16.6.1.1. XX Driving/Opportunity Factor
16.6.1.2. XX Driving/Opportunity Factor
16.7. MEA Hereditary Angioedema Treatment Market Size and Forecast By Route of Administration
16.7.1.1. XX Driving/Opportunity Factor
16.7.1.2. XX Driving/Opportunity Factor
16.8. MEA Hereditary Angioedema Treatment Market Size and Forecast By End-User
16.8.1.1. XX Driving/Opportunity Factor
16.8.1.2. XX Driving/Opportunity Factor
16.9. MEA Hereditary Angioedema Treatment Market Size and Forecast By Distribution Channel
16.9.1.1. XX Driving/Opportunity Factor
16.9.1.2. XX Driving/Opportunity Factor
16.10. GCC Hereditary Angioedema Treatment Market
16.10.1.1. XX Driving/Opportunity Factor
16.10.1.2. XX Driving/Opportunity Factor
16.11. South Africa Hereditary Angioedema Treatment Market
16.11.1.1. XX Driving/Opportunity Factor
16.11.1.2. XX Driving/Opportunity Factor
16.12. Rest of MEA Hereditary Angioedema Treatment Market
16.12.1.1. XX Driving/Opportunity Factor
16.12.1.2. XX Driving/Opportunity Factor
17. Companies in the Hereditary Angioedema Treatment Market
17.1. Shire Plc
17.1.1. Company Snapshot
17.1.2. Company Overview
17.1.3. Financial Performance (2015-2019)
17.1.3.1. Net Revenue
17.1.3.2. Gross Profit
17.1.3.3. Geographical Revenue, 2019
17.1.4. Product Offerings
17.1.5. Recent Initiatives (2017-2019)
17.2. BioCryst Pharmaceuticals, Inc.
17.2.1. Company Snapshot
17.2.2. Company Overview
17.2.3. Financial Performance (2015-2019)
17.2.3.1. Net Revenue
17.2.3.2. Gross Profit
17.2.3.3. Geographical Revenue, 2019
17.2.4. Product Offerings
17.2.5. Recent Initiatives (2017-2019)
17.3. Ionis Pharmaceuticals, Inc.
17.3.1. Company Snapshot
17.3.2. Company Overview
17.3.3. Financial Performance (2015-2019)
17.3.3.1. Net Revenue
17.3.3.2. Gross Profit
17.3.3.3. Geographical Revenue, 2019
17.3.4. Product Offerings
17.3.5. Recent Initiatives (2017-2019)
17.4. Pharming Group N.V.
17.4.1. Company Snapshot
17.4.2. Company Overview
17.4.3. Financial Performance (2015-2019)
17.4.3.1. Net Revenue
17.4.3.2. Gross Profit
17.4.3.3. Geographical Revenue, 2019
17.4.4. Product Offerings
17.4.5. Recent Initiatives (2017-2019)
17.5. CSL Limited
17.5.1. Company Snapshot
17.5.2. Company Overview
17.5.3. Financial Performance (2015-2019)
17.5.3.1. Net Revenue
17.5.3.2. Gross Profit
17.5.3.3. Geographical Revenue, 2019
17.5.4. Product Offerings
17.5.5. Recent Initiatives (2017-2019)
17.6. Attune Pharmaceuticals, Inc.
17.6.1. Company Snapshot
17.6.2. Company Overview
17.6.3. Financial Performance (2015-2019)
17.6.3.1. Net Revenue
17.6.3.2. Gross Profit
17.6.3.3. Geographical Revenue, 2019
17.6.4. Product Offerings
17.6.5. Recent Initiatives (2017-2019)
17.7. Adverum Biotechnologies, Inc.
17.7.1. Company Snapshot
17.7.2. Company Overview
17.7.3. Financial Performance (2015-2019)
17.7.3.1. Net Revenue
17.7.3.2. Gross Profit
17.7.3.3. Geographical Revenue, 2019
17.7.4. Product Offerings
17.7.5. Recent Initiatives (2017-2019)
17.8. KalVista Pharmaceuticals, Inc.
17.8.1. Company Snapshot
17.8.2. Company Overview
17.8.3. Financial Performance (2015-2019)
17.8.3.1. Net Revenue
17.8.3.2. Gross Profit
17.8.3.3. Geographical Revenue, 2019
17.8.4. Product Offerings
17.8.5. Recent Initiatives (2017-2019)
17.9. Takeda Pharmaceutical Company Limited
17.9.1. Company Snapshot
17.9.2. Company Overview
17.9.3. Financial Performance (2015-2019)
17.9.3.1. Net Revenue
17.9.3.2. Gross Profit
17.9.3.3. Geographical Revenue, 2019
17.9.4. Product Offerings
17.9.5. Recent Initiatives (2017-2019)
17.10. Pharming Healthcare, Inc.
17.10.1. Company Snapshot
17.10.2. Company Overview
17.10.3. Financial Performance (2015-2019)
17.10.3.1. Net Revenue
17.10.3.2. Gross Profit
17.10.3.3. Geographical Revenue, 2019
17.10.4. Product Offerings
17.10.5. Recent Initiatives (2017-2019)
17.11. Other Notable Players
18. Conclusion
19. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Hereditary Angioedema Treatment Market Drivers & Restraints 2021
Table 7. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 223. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 248. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 253. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 417. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 418. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 419. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 420. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 421. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 422. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 423. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 424. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 425. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 426. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 427. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 428. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 429. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 430. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 431. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 432. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 433. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 434. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 435. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 436. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 437. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 438. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 439. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 440. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 441. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 442. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 443. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 444. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 445. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 446. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 447. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 448. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 449. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 450. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 451. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 452. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 453. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 454. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 455. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 456. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 457. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 458. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 459. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 460. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 461. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 462. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 463. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 464. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 465. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 466. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 467. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 468. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 469. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 470. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 471. Leading 10 Hereditary Angioedema Treatment Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 472. Shire PlcProfile 2019 (CEO, HQ, Founded, Website)
Table 473. Shire Plc Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 474. BioCryst Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 475. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 476. Ionis Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 477. Ionis Pharmaceuticals, Inc..Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 478. Pharming Group N.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 479. Pharming Group N.V. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 480. CSL Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 481. CSL Limited Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 482. Attune Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 483. Attune Pharmaceuticals, Inc. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 484. Adverum Biotechnologies, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 485. Adverum Biotechnologies, Inc. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 486. KalVista Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 487. KalVista Pharmaceuticals, Inc. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 488. Takeda Pharmaceutical Company Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 489. Takeda Pharmaceutical Company Limited Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 490. Pharming Healthcare, Inc. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 491. Pharming Healthcare, Inc. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 492. Other Companies Involved in the Hereditary Angioedema Treatment Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Hereditary Angioedema Treatment Market Drivers & Restraints 2021
Figure 7. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 223. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 248. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 249. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 250. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 251. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 252. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 253. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 254. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 255. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 256. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 257. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 258. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 259. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 260. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 261. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 262. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 417. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 418. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 419. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 420. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 421. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 422. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 423. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 424. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 425. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 426. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 427. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 428. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 429. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 430. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 431. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 432. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 433. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 434. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 435. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 436. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 437. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 438. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 439. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 440. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 441. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 442. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 443. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 444. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 445. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 446. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 447. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 448. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 449. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 450. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 451. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 452. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 453. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 454. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 455. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 456. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 457. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 458. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 459. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 460. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 461. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 462. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 463. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 464. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 465. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 466. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 467. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 468. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 469. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 470. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 471. Porter’s Five Force Analysis
Companies Mentioned
1. Abbott
2. AbbVie
3. Achaogen
4. Actavis
5. Actelion
6. Affinium Pharmaceutical
7. AiCuris GmbH & Co. KG
8. Alcon
9. Alkem Laboratories
10. Allergan
11. Allied Pharma
12. Apotex
13. APP Pharmaceuticals
14. Aptalis Pharma
15. Aquapharm Biodiscovery
16. Cempra Pharmaceuticals
17. Cipla
18. Claris Lifesciences
19. Cornerstone Biopharma
20. Cornerstone Therapeutics
21. Corona Remedies
22. Eli Lilly
23. Gate Pharma
24. Gilead Sciences
25. GlaxoSmithKline (GSK)
26. Glenmark
27. GlycoVaxyn
28. Hetero
29. Hikma Farmaceutica
30. Hi-Tech Pharma
31. Hospira
32. Macleod Pharmaceuticals
33. Microlabs
34. Nalneva
35. Novartis
36. Novexel
37. Paratek Pharmaceuticals
38. Pfizer
39. Ranbaxy
40. Roche
41. Sagent Pharmaceuticals
42. Sandoz
43. Sanofi
44. Sequella
45. Shanghai MengKe Pharmaceuticals
46. Shionogi
47. SHIONOGI Co., Ltd.
48. Shire
49. Sidmak Labs
50. Solitaire Pharmacia
51. Specialised Therapeutics Australia
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Hereditary Angioedema Treatment Market
2.1. Hereditary Angioedema Treatment Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Hereditary Angioedema Treatment Market Overview
3.1. Global Hereditary Angioedema Treatment Market Size and Forecast By Region
3.2. Global Hereditary Angioedema Treatment Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Prevalence of hereditary angioedema disorders
3.3.1.2. Increasing geriatric population around the World
3.3.1.3. Increasing therapeutic advancement in hereditary angioedema treatment
3.3.1.4. Increasing strategic initiatives in hereditary angioedema treatment market
3.3.1.5. Surging investment in hereditary angioedema treatment
3.3.2. Market Restraints
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High Cost of development
3.3.2.3. Product Recall
3.3.3. Opportunities
3.3.3.1. Increasing focus on advance therapeutics
3.3.3.2. Increasing focus on healthcare infrastructure
3.3.4. Challenges
3.3.4.1. Safety consideration in storage & transportation
3.3.4.2. Increasing competition in the market
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Hereditary Angioedema Treatment Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. C1-esterase Inhibitor
4.1.1.1. C1-esterase Inhibitor Market size and forecast, 2021-2031 (USD Million)
4.1.2. Bradykinin B2 Receptor Antagonist
4.1.2.1. Bradykinin B2 Receptor Antagonist Market size and forecast, 2021-2031 (USD Million)
4.1.3. Kallikrein Inhibitor
4.1.3.1. Kallikrein Inhibitor Market size and forecast, 2021-2031 (USD Million)
4.1.4. Others
4.1.4.1. Others Market size and forecast, 2021-2031 (USD Million)
5. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Treatment (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Prophylaxis
5.1.1.1. Prophylaxis Market size and forecast, 2021-2031 (USD Million)
5.1.2. On-demand
5.1.2.1. On-demand Market size and forecast, 2021-2031 (USD Million)
6. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Type I HAE
6.1.1.1. Type I HAE Market size and forecast, 2021-2031 (USD Million)
6.1.2. Type II HAE
6.1.2.1. Type II HAE Market size and forecast, 2021-2031 (USD Million)
6.1.3. Type III HAE
6.1.3.1. Type III HAE Market size and forecast, 2021-2031 (USD Million)
7. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Geriatric Patient
7.1.1.1. Geriatric Patient Market size and forecast, 2021-2031 (USD Million)
7.1.2. Adult Patient
7.1.2.1. Adult Patient Market size and forecast, 2021-2031 (USD Million)
7.1.3. Pediatric
7.1.3.1. Pediatric Market size and forecast, 2021-2031 (USD Million)
8. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Generic Drugs
8.1.1.1. Generic Drugs Market size and forecast, 2021-2031 (USD Million)
8.1.2. Branded Drugs
8.1.2.1. Branded Drugs Market size and forecast, 2021-2031 (USD Million)
9. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Oral
9.1.1.1. Oral Market size and forecast, 2021-2031 (USD Million)
9.1.2. Subcutaneous
9.1.2.1. Subcutaneous Market size and forecast, 2021-2031 (USD Million)
9.1.3. Intravenous
9.1.3.1. Intravenous Market size and forecast, 2021-2031 (USD Million)
10. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals
10.1.1.1. Hospitals Market size and forecast, 2021-2031 (USD Million)
10.1.2. Homecare
10.1.2.1. Homecare Market size and forecast, 2021-2031 (USD Million)
10.1.3. Specialty Clinics
10.1.3.1. Specialty Clinics Market size and forecast, 2021-2031 (USD Million)
10.1.4. Others
10.1.4.1. Others Market size and forecast, 2021-2031 (USD Million)
11. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.1.1. Hospitals Pharmacy
11.1.1.1. Hospitals Pharmacy Market size and forecast, 2021-2031 (USD Million)
11.1.2. Retail Pharmacy
11.1.2.1. Retail Pharmacy Market size and forecast, 2021-2031 (USD Million)
11.1.3. Online Pharmacies
11.1.3.1. Online Pharmacies Market size and forecast, 2021-2031 (USD Million)
12. North America Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. North America Hereditary Angioedema Treatment Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. North America Hereditary Angioedema Treatment Market Size and Forecast By Treatment
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. North America Hereditary Angioedema Treatment Market Size and Forecast By Drug Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. North America Hereditary Angioedema Treatment Market Size and Forecast By Patient Demographics
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. North America Hereditary Angioedema Treatment Market Size and Forecast By Type
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. North America Hereditary Angioedema Treatment Market Size and Forecast By Route of Administration
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. North America Hereditary Angioedema Treatment Market Size and Forecast By End-User
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. North America Hereditary Angioedema Treatment Market Size and Forecast By Distribution Channel
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. U.S. Hereditary Angioedema Treatment Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Canada Hereditary Angioedema Treatment Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Europe Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Europe Hereditary Angioedema Treatment Market Size and Forecast By Drug Class
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Europe Hereditary Angioedema Treatment Market Size and Forecast By Treatment
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Europe Hereditary Angioedema Treatment Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Europe Hereditary Angioedema Treatment Market Size and Forecast By Type
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Europe Hereditary Angioedema Treatment Market Size and Forecast By Drug Type
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Europe Hereditary Angioedema Treatment Market Size and Forecast By Route of Administration
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Europe Hereditary Angioedema Treatment Market Size and Forecast By End-User
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Europe Hereditary Angioedema Treatment Market Size and Forecast By Distribution Channel
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. UK Hereditary Angioedema Treatment Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Germany Hereditary Angioedema Treatment Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. France Hereditary Angioedema Treatment Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
13.13. Rest of Europe Hereditary Angioedema Treatment Market
13.13.1.1. XX Driving/Opportunity Factor
13.13.1.2. XX Driving/Opportunity Factor
14. Asia Pacific Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Drug Class
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Treatment
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Type
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Drug Type
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Route of Administration
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By End-User
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. Asia-Pacific Hereditary Angioedema Treatment Market Size and Forecast By Distribution Channel
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. China Hereditary Angioedema Treatment Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. India Hereditary Angioedema Treatment Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
14.12. Japan Hereditary Angioedema Treatment Market
14.12.1.1. XX Driving/Opportunity Factor
14.12.1.2. XX Driving/Opportunity Factor
14.13. Rest of Asia Pacific Hereditary Angioedema Treatment Market
14.13.1.1. XX Driving/Opportunity Factor
14.13.1.2. XX Driving/Opportunity Factor
15. Latin America Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Drug Class
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Treatment
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Patient Demographics
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Drug Type
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Type
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Route of Administration
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. Latin America Hereditary Angioedema Treatment Market Size and Forecast By End-User
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. Latin America Hereditary Angioedema Treatment Market Size and Forecast By Distribution Channel
15.10. Brazil Hereditary Angioedema Treatment Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Mexico Hereditary Angioedema Treatment Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
15.12. Rest of Latin America Hereditary Angioedema Treatment Market
15.12.1.1. XX Driving/Opportunity Factor
15.12.1.2. XX Driving/Opportunity Factor
16. MEA Hereditary Angioedema Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
16.1. Market Overview
16.2. MEA Hereditary Angioedema Treatment Market Size and Forecast By Drug Class
16.2.1.1. XX Driving/Opportunity Factor
16.2.1.2. XX Driving/Opportunity Factor
16.3. MEA Hereditary Angioedema Treatment Market Size and Forecast By Treatment
16.3.1.1. XX Driving/Opportunity Factor
16.3.1.2. XX Driving/Opportunity Factor
16.4. MEA Hereditary Angioedema Treatment Market Size and Forecast By Patient Demographics
16.4.1.1. XX Driving/Opportunity Factor
16.4.1.2. XX Driving/Opportunity Factor
16.5. MEA Hereditary Angioedema Treatment Market Size and Forecast By Drug Type
16.5.1.1. XX Driving/Opportunity Factor
16.5.1.2. XX Driving/Opportunity Factor
16.6. MEA Hereditary Angioedema Treatment Market Size and Forecast By Type
16.6.1.1. XX Driving/Opportunity Factor
16.6.1.2. XX Driving/Opportunity Factor
16.7. MEA Hereditary Angioedema Treatment Market Size and Forecast By Route of Administration
16.7.1.1. XX Driving/Opportunity Factor
16.7.1.2. XX Driving/Opportunity Factor
16.8. MEA Hereditary Angioedema Treatment Market Size and Forecast By End-User
16.8.1.1. XX Driving/Opportunity Factor
16.8.1.2. XX Driving/Opportunity Factor
16.9. MEA Hereditary Angioedema Treatment Market Size and Forecast By Distribution Channel
16.9.1.1. XX Driving/Opportunity Factor
16.9.1.2. XX Driving/Opportunity Factor
16.10. GCC Hereditary Angioedema Treatment Market
16.10.1.1. XX Driving/Opportunity Factor
16.10.1.2. XX Driving/Opportunity Factor
16.11. South Africa Hereditary Angioedema Treatment Market
16.11.1.1. XX Driving/Opportunity Factor
16.11.1.2. XX Driving/Opportunity Factor
16.12. Rest of MEA Hereditary Angioedema Treatment Market
16.12.1.1. XX Driving/Opportunity Factor
16.12.1.2. XX Driving/Opportunity Factor
17. Companies in the Hereditary Angioedema Treatment Market
17.1. Shire Plc
17.1.1. Company Snapshot
17.1.2. Company Overview
17.1.3. Financial Performance (2015-2019)
17.1.3.1. Net Revenue
17.1.3.2. Gross Profit
17.1.3.3. Geographical Revenue, 2019
17.1.4. Product Offerings
17.1.5. Recent Initiatives (2017-2019)
17.2. BioCryst Pharmaceuticals, Inc.
17.2.1. Company Snapshot
17.2.2. Company Overview
17.2.3. Financial Performance (2015-2019)
17.2.3.1. Net Revenue
17.2.3.2. Gross Profit
17.2.3.3. Geographical Revenue, 2019
17.2.4. Product Offerings
17.2.5. Recent Initiatives (2017-2019)
17.3. Ionis Pharmaceuticals, Inc.
17.3.1. Company Snapshot
17.3.2. Company Overview
17.3.3. Financial Performance (2015-2019)
17.3.3.1. Net Revenue
17.3.3.2. Gross Profit
17.3.3.3. Geographical Revenue, 2019
17.3.4. Product Offerings
17.3.5. Recent Initiatives (2017-2019)
17.4. Pharming Group N.V.
17.4.1. Company Snapshot
17.4.2. Company Overview
17.4.3. Financial Performance (2015-2019)
17.4.3.1. Net Revenue
17.4.3.2. Gross Profit
17.4.3.3. Geographical Revenue, 2019
17.4.4. Product Offerings
17.4.5. Recent Initiatives (2017-2019)
17.5. CSL Limited
17.5.1. Company Snapshot
17.5.2. Company Overview
17.5.3. Financial Performance (2015-2019)
17.5.3.1. Net Revenue
17.5.3.2. Gross Profit
17.5.3.3. Geographical Revenue, 2019
17.5.4. Product Offerings
17.5.5. Recent Initiatives (2017-2019)
17.6. Attune Pharmaceuticals, Inc.
17.6.1. Company Snapshot
17.6.2. Company Overview
17.6.3. Financial Performance (2015-2019)
17.6.3.1. Net Revenue
17.6.3.2. Gross Profit
17.6.3.3. Geographical Revenue, 2019
17.6.4. Product Offerings
17.6.5. Recent Initiatives (2017-2019)
17.7. Adverum Biotechnologies, Inc.
17.7.1. Company Snapshot
17.7.2. Company Overview
17.7.3. Financial Performance (2015-2019)
17.7.3.1. Net Revenue
17.7.3.2. Gross Profit
17.7.3.3. Geographical Revenue, 2019
17.7.4. Product Offerings
17.7.5. Recent Initiatives (2017-2019)
17.8. KalVista Pharmaceuticals, Inc.
17.8.1. Company Snapshot
17.8.2. Company Overview
17.8.3. Financial Performance (2015-2019)
17.8.3.1. Net Revenue
17.8.3.2. Gross Profit
17.8.3.3. Geographical Revenue, 2019
17.8.4. Product Offerings
17.8.5. Recent Initiatives (2017-2019)
17.9. Takeda Pharmaceutical Company Limited
17.9.1. Company Snapshot
17.9.2. Company Overview
17.9.3. Financial Performance (2015-2019)
17.9.3.1. Net Revenue
17.9.3.2. Gross Profit
17.9.3.3. Geographical Revenue, 2019
17.9.4. Product Offerings
17.9.5. Recent Initiatives (2017-2019)
17.10. Pharming Healthcare, Inc.
17.10.1. Company Snapshot
17.10.2. Company Overview
17.10.3. Financial Performance (2015-2019)
17.10.3.1. Net Revenue
17.10.3.2. Gross Profit
17.10.3.3. Geographical Revenue, 2019
17.10.4. Product Offerings
17.10.5. Recent Initiatives (2017-2019)
17.11. Other Notable Players
18. Conclusion
19. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Hereditary Angioedema Treatment Market Drivers & Restraints 2021
Table 7. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 223. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 248. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 253. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 417. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 418. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 419. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 420. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 421. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 422. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 423. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 424. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 425. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 426. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 427. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 428. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 429. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 430. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 431. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 432. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 433. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 434. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 435. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 436. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 437. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 438. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 439. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 440. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 441. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 442. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 443. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 444. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 445. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 446. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 447. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 448. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 449. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 450. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 451. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 452. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 453. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 454. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 455. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 456. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 457. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 458. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 459. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 460. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 461. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 462. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 463. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 464. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 465. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 466. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 467. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 468. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 469. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 470. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 471. Leading 10 Hereditary Angioedema Treatment Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 472. Shire PlcProfile 2019 (CEO, HQ, Founded, Website)
Table 473. Shire Plc Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 474. BioCryst Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 475. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 476. Ionis Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 477. Ionis Pharmaceuticals, Inc..Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 478. Pharming Group N.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 479. Pharming Group N.V. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 480. CSL Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 481. CSL Limited Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 482. Attune Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 483. Attune Pharmaceuticals, Inc. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 484. Adverum Biotechnologies, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 485. Adverum Biotechnologies, Inc. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 486. KalVista Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 487. KalVista Pharmaceuticals, Inc. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 488. Takeda Pharmaceutical Company Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 489. Takeda Pharmaceutical Company Limited Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 490. Pharming Healthcare, Inc. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 491. Pharming Healthcare, Inc. Hereditary Angioedema Treatment Product Offering (Segment, Product Offerings)
Table 492. Other Companies Involved in the Hereditary Angioedema Treatment Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Hereditary Angioedema Treatment Market Drivers & Restraints 2021
Figure 7. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. C1-esterase Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Bradykinin B2 Receptor Antagonist Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Kallikrein Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Prophylaxis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. On-demand Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Type I HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Type II HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Type III HAE Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Subcutaneous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. North America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. North America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. North America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. North America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. US Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. Canada Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 223. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Europe Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. Europe Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. Europe Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. Europe Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. Europe Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 248. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 249. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 250. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 251. Europe Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 252. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 253. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 254. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 255. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 256. Europe Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 257. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 258. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 259. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 260. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 261. Europe Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 262. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Europe Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. UK Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Germany Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. France Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Rest of Europe Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Asia Pacific Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Asia Pacific Hereditary Angioedema Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. China Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. India Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Japan Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. RoAPAC Hereditary Angioedema Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Middle East Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Middle East Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Middle East Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Middle East Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Middle East Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Middle East Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Middle East Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Latin America Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Latin America Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Latin America Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Latin America Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 417. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 418. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 419. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 420. Latin America Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 421. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 422. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 423. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 424. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 425. Latin America Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 426. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 427. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 428. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 429. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 430. Latin America Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 431. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 432. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 433. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 434. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 435. Africa Hereditary Angioedema Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 436. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 437. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 438. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 439. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 440. Africa Hereditary Angioedema Treatment Market Forecast By Treatment 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 441. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 442. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 443. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 444. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 445. Africa Hereditary Angioedema Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 446. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 447. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 448. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 449. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 450. Africa Hereditary Angioedema Treatment Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 451. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 452. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 453. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 454. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 455. Africa Hereditary Angioedema Treatment Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 456. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 457. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 458. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 459. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 460. Africa Hereditary Angioedema Treatment Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 461. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 462. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 463. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 464. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 465. Africa Hereditary Angioedema Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 466. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 467. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 468. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 469. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 470. Africa Hereditary Angioedema Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 471. Porter’s Five Force Analysis
Companies Mentioned
1. Abbott
2. AbbVie
3. Achaogen
4. Actavis
5. Actelion
6. Affinium Pharmaceutical
7. AiCuris GmbH & Co. KG
8. Alcon
9. Alkem Laboratories
10. Allergan
11. Allied Pharma
12. Apotex
13. APP Pharmaceuticals
14. Aptalis Pharma
15. Aquapharm Biodiscovery
16. Cempra Pharmaceuticals
17. Cipla
18. Claris Lifesciences
19. Cornerstone Biopharma
20. Cornerstone Therapeutics
21. Corona Remedies
22. Eli Lilly
23. Gate Pharma
24. Gilead Sciences
25. GlaxoSmithKline (GSK)
26. Glenmark
27. GlycoVaxyn
28. Hetero
29. Hikma Farmaceutica
30. Hi-Tech Pharma
31. Hospira
32. Macleod Pharmaceuticals
33. Microlabs
34. Nalneva
35. Novartis
36. Novexel
37. Paratek Pharmaceuticals
38. Pfizer
39. Ranbaxy
40. Roche
41. Sagent Pharmaceuticals
42. Sandoz
43. Sanofi
44. Sequella
45. Shanghai MengKe Pharmaceuticals
46. Shionogi
47. SHIONOGI Co., Ltd.
48. Shire
49. Sidmak Labs
50. Solitaire Pharmacia
51. Specialised Therapeutics Australia
Companies Profiled in the Report
1. Shire Plc
2. BioCryst Pharmaceuticals, Inc.
3. Ionis Pharmaceuticals, Inc.
4. Pharming Group N.V.
5. CSL Limited
6. Attune Pharmaceuticals, Inc.
7. Adverum Biotechnologies, Inc.
8. KalVista Pharmaceuticals, Inc.
9. Takeda Pharmaceutical Company Limited
10. Pharming Healthcare, Inc.
List of Companies Mentioned in the Report:
1. Abbott
2. AbbVie
3. Achaogen
4. Actavis
5. Actelion
6. Affinium Pharmaceutical
7. AiCuris GmbH & Co. KG
8. Alcon
9. Alkem Laboratories
10. Allergan
11. Allied Pharma
12. Apotex
13. APP Pharmaceuticals
14. Aptalis Pharma
15. Aquapharm Biodiscovery
16. Cempra Pharmaceuticals
17. Cipla
18. Claris Lifesciences
19. Cornerstone Biopharma
20. Cornerstone Therapeutics
21. Corona Remedies
22. Eli Lilly
23. Gate Pharma
24. Gilead Sciences
25. GlaxoSmithKline (GSK)
26. Glenmark
27. GlycoVaxyn
28. Hetero
29. Hikma Farmaceutica
30. Hi-Tech Pharma
31. Hospira
32. Macleod Pharmaceuticals
33. Microlabs
34. Nalneva
35. Novartis
36. Novexel
37. Paratek Pharmaceuticals
38. Pfizer
39. Ranbaxy
40. Roche
41. Sagent Pharmaceuticals
42. Sandoz
43. Sanofi
44. Sequella
45. Shanghai MengKe Pharmaceuticals
46. Shionogi
47. SHIONOGI Co., Ltd.
48. Shire
49. Sidmak Labs
50. Solitaire Pharmacia
51. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. European Medicines Agency (EMA)
2. Food and Drug Administration (FDA)
3. National Institutes of Health (NIH)
4. United Nations (UN)
5. United Nations Office on Drugs and Crime (UNODC)
6. United Nations Statistics Division (UNSD)
7. Statistical Office of the European Union (EUROSTAT)
8. University of Connecticut
9. World Health Organization (WHO)
10. The National Medical Products Administration (NMPA)
11. Indian Council of Medical Research (ICMR)
12. The Therapeutic Goods Administration
13. The Federal Institute for Drugs and Medical Devices (BfArM)
14. Pharmaceuticals and Medical Devices Agency (PMDA)
15. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
16. Ministry of Health, Labour & Welfare(MHLW)
17. Medicines and Healthcare Products Regulatory Agency (MHRA)
18. Centre for Pharmaceutical Administration Health Sciences Authority
19. Central Drug Standard Control Organization (CDSCO)
20. Organisation for Economic Co-operation and Development (OECD)
1. Shire Plc
2. BioCryst Pharmaceuticals, Inc.
3. Ionis Pharmaceuticals, Inc.
4. Pharming Group N.V.
5. CSL Limited
6. Attune Pharmaceuticals, Inc.
7. Adverum Biotechnologies, Inc.
8. KalVista Pharmaceuticals, Inc.
9. Takeda Pharmaceutical Company Limited
10. Pharming Healthcare, Inc.
List of Companies Mentioned in the Report:
1. Abbott
2. AbbVie
3. Achaogen
4. Actavis
5. Actelion
6. Affinium Pharmaceutical
7. AiCuris GmbH & Co. KG
8. Alcon
9. Alkem Laboratories
10. Allergan
11. Allied Pharma
12. Apotex
13. APP Pharmaceuticals
14. Aptalis Pharma
15. Aquapharm Biodiscovery
16. Cempra Pharmaceuticals
17. Cipla
18. Claris Lifesciences
19. Cornerstone Biopharma
20. Cornerstone Therapeutics
21. Corona Remedies
22. Eli Lilly
23. Gate Pharma
24. Gilead Sciences
25. GlaxoSmithKline (GSK)
26. Glenmark
27. GlycoVaxyn
28. Hetero
29. Hikma Farmaceutica
30. Hi-Tech Pharma
31. Hospira
32. Macleod Pharmaceuticals
33. Microlabs
34. Nalneva
35. Novartis
36. Novexel
37. Paratek Pharmaceuticals
38. Pfizer
39. Ranbaxy
40. Roche
41. Sagent Pharmaceuticals
42. Sandoz
43. Sanofi
44. Sequella
45. Shanghai MengKe Pharmaceuticals
46. Shionogi
47. SHIONOGI Co., Ltd.
48. Shire
49. Sidmak Labs
50. Solitaire Pharmacia
51. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. European Medicines Agency (EMA)
2. Food and Drug Administration (FDA)
3. National Institutes of Health (NIH)
4. United Nations (UN)
5. United Nations Office on Drugs and Crime (UNODC)
6. United Nations Statistics Division (UNSD)
7. Statistical Office of the European Union (EUROSTAT)
8. University of Connecticut
9. World Health Organization (WHO)
10. The National Medical Products Administration (NMPA)
11. Indian Council of Medical Research (ICMR)
12. The Therapeutic Goods Administration
13. The Federal Institute for Drugs and Medical Devices (BfArM)
14. Pharmaceuticals and Medical Devices Agency (PMDA)
15. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
16. Ministry of Health, Labour & Welfare(MHLW)
17. Medicines and Healthcare Products Regulatory Agency (MHRA)
18. Centre for Pharmaceutical Administration Health Sciences Authority
19. Central Drug Standard Control Organization (CDSCO)
20. Organisation for Economic Co-operation and Development (OECD)
Download sample pages
Complete the form below to download your free sample pages for Hereditary Angioedema Treatment Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Hereditary Angioedema Treatment Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Bioreactors Market Report 2023-2033
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
21 September 2023
